---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effects of other drugs"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effects of other drugs. Topics: Strong CYP3A4 inhibitors and inducers in the phase 1/2 study, Medications with a known risk of QT prolongation, Proton pump inhibitors and antiemetics, CYP3A4 metabolism and sensitivity to inhibition, and 5 further topics. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Palazestrant

<a id="topic-2.1.2.9.1-1"></a>

### Strong CYP3A4 inhibitors and inducers in the phase 1/2 study

> “any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.9.1-2"></a>

### Medications with a known risk of QT prolongation

> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.9.1-3"></a>

### Proton pump inhibitors and antiemetics

> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.9.1-4"></a>

### CYP3A4 metabolism and sensitivity to inhibition

> “Ribociclib is a strong inhibitor of CYP3A4. While palazestrant is metabolized by CYP3A4, it is not sensitive to CYP3A4 inhibition.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.1-5"></a>

### Effect of ribociclib on palazestrant trough concentrations

> “Steady-state trough values overlapped between the combination and single agent palazestrant, with a small increase in mean exposure (Table 4). The effect of ribociclib on the exposure of palazestrant is not clinically meaningful.”

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.1-6"></a>

### Dose-normalized palazestrant trough concentrations with and without ribociclib

| Study | Dose-normalized steady-state trough, geometric mean (geometric SD); n | 90% confidence interval |
| --- | --- | --- |
| OP-1250-001, single agent | “2.49 (48%); 172” | “[2.35, 2.64]” |
| OP-1250-003, combination with ribociclib | “3.35 (61%); 25” | “[2.77, 4.06]” |

Source: [Borges et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-003_12-5-23.pdf)

<a id="topic-2.1.2.9.1-7"></a>

### Ribociclib and palazestrant exposure at the September 2024 data cutoff

> “Steady-state trough values between the combination and single-agent palazestrant were overlapping.”

Source: [Borges et al. (2024b)](https://ir.olema.com/static-files/dfb83ebb-df49-47a3-a585-ec416cc48954)

<a id="topic-2.1.2.9.1-8"></a>

### Ribociclib and palazestrant exposure at the July 2025 data cutoff

> “Ribociclib had no clinically meaningful effect on palazestrant exposure”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.9.1-9"></a>

### Effect of palbociclib on palazestrant exposure

> “Palbociclib 125 mg did not affect palazestrant (30-120 mg) exposure parameters.”

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
